Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.10 -1.2%	$17.97	$13.50 ▼ $25.67	$4.13B	0.38	3.44 million shs	1.90 million shs
AKRO Akero Therapeutics	$48.29 +0.7%	$51.59	$21.34 ▼ $58.40	$3.84B	-0.28	1.09 million shs	534,807 shs
DYN Dyne Therapeutics	$12.22 +2.1%	$10.27	$6.36 ▼ $47.06	$1.70B	1.08	3.06 million shs	1.60 million shs
RNA Avidity Biosciences	$44.66 +0.7%	$35.33	$21.51 ▼ $56.00	$5.70B	0.95	3.90 million shs	1.22 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-0.80%	+0.58%	+0.99%	-14.19%	-3.51%
AKRO Akero Therapeutics	+0.74%	-0.75%	-6.68%	-2.08%	+79.32%
DYN Dyne Therapeutics	-2.29%	-2.21%	+30.53%	+0.59%	-74.43%
RNA Avidity Biosciences	+0.73%	-4.28%	+30.34%	+43.91%	-1.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.3541 of 5 stars	3.7	3.0	0.0	3.7	2.5	3.1
AKRO Akero Therapeutics	3.9484 of 5 stars	3.5	2.0	4.7	3.3	0.8	0.0
DYN Dyne Therapeutics	3.0883 of 5 stars	4.5	1.0	0.0	1.3	4.2	0.0
RNA Avidity Biosciences	3.157 of 5 stars	4.5	2.0	0.0	3.9	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	61.79% Upside
AKRO Akero Therapeutics	3.00	Buy	$81.57	68.92% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	176.60% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	50.02% Upside

Current Analyst Ratings Breakdown

Latest DYN, RNA, AKRO, and ADMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.57	$0.53 per share	32.22	$1.67 per share	10.24
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$12.82 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$4.02 per share	N/A
RNA Avidity Biosciences	$10.73M	535.52	N/A	N/A	$9.27 per share	4.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.86	19.88	24.78	N/A	44.06%	41.01%	28.47%	11/6/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	N/A
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	N/A
RNA Avidity Biosciences	-$322.30M	-$3.56	N/A	N/A	N/A	-4,247.77%	-33.45%	-30.22%	11/6/2025 (Estimated)

Latest DYN, RNA, AKRO, and ADMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	$0.15	+$0.01	$0.14	$121.77 million	$121.98 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.21	5.33	2.78
AKRO Akero Therapeutics	0.02	12.66	12.66
DYN Dyne Therapeutics	0.17	16.83	16.83
RNA Avidity Biosciences	N/A	9.26	9.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AKRO Akero Therapeutics	N/A
DYN Dyne Therapeutics	96.68%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
AKRO Akero Therapeutics	7.07%
DYN Dyne Therapeutics	14.14%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.63 million	230.28 million	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	122.15 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable

DYN, RNA, AKRO, and ADMA Headlines

Recent News About These Companies

Avidity Biosciences Sees Unusually High Options Volume (NASDAQ:RNA)

3 hours ago | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Down 4.2% on Insider Selling

August 20 at 3:46 PM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $67.00 Consensus PT from Analysts

August 20 at 3:01 AM | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Down 4.2% on Insider Selling

August 20 at 2:35 AM | americanbankingnews.com

Avidity Biosciences, Inc. $RNA Holdings Cut by Vanguard Group Inc.

August 19 at 3:59 AM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Citigroup Inc.

August 18 at 3:54 AM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Deutsche Bank AG

August 18 at 3:37 AM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $465,600.00 in Stock

August 17, 2025 | marketbeat.com

Teresa Mccarthy Sells 10,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

August 16, 2025 | insidertrades.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Buy" by Analysts

August 16, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down on Insider Selling

August 12, 2025 | marketbeat.com

What is Leerink Partnrs' Estimate for RNA FY2027 Earnings?

August 12, 2025 | marketbeat.com

Mackenzie Financial Corp Invests $213,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)

August 11, 2025 | marketbeat.com

Wells Fargo & Company Forecasts Strong Price Appreciation for Avidity Biosciences (NASDAQ:RNA) Stock

August 11, 2025 | americanbankingnews.com

Troy Edward Wilson Sells 65,554 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

August 10, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Steven George Hughes Sells 81,434 Shares

August 10, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $5,119,150.00 in Stock

August 10, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Eric Mosbrooker Sells 130,807 Shares

August 10, 2025 | marketbeat.com

The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

August 10, 2025 | finance.yahoo.com

Avidity (RNA) Q2 Revenue Jumps 88%

August 9, 2025 | theglobeandmail.com

Wells Fargo & Company Issues Positive Forecast for Avidity Biosciences (NASDAQ:RNA) Stock Price

August 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DYN, RNA, AKRO, and ADMA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.10 -0.20 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$16.98 -0.12 (-0.70%)

As of 06:35 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Akero Therapeutics NASDAQ:AKRO

$48.29 +0.34 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$49.00 +0.70 (+1.46%)

As of 04:52 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Dyne Therapeutics NASDAQ:DYN

$12.22 +0.25 (+2.09%)

Closing price 04:00 PM Eastern

Extended Trading

$12.23 +0.01 (+0.08%)

As of 06:03 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$44.66 +0.32 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$44.88 +0.22 (+0.48%)

As of 06:07 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time